The different forms of tirzepatide available in the UK

The myth: tirzepatide comes in several forms you can choose between

Spend ten minutes reading weight-loss forums and you'll find confident claims that tirzepatide is available as a tablet, a patch or a compounded liquid. None of that is accurate in the UK right now. The only MHRA-licensed form of tirzepatide for weight management is Mounjaro, a pre-filled KwikPen that delivers a once-weekly subcutaneous injection. Eli Lilly, the manufacturer, has not gained UK approval for any other delivery format for this medicine. When a seller claims to offer an oral or topical tirzepatide product, that is not a licensed UK medicine, and buying it carries real risk.

The confusion is understandable. A number of GLP-1 medicines are now in development as tablets (oral tirzepatide research is ongoing) and the recent MHRA approval of the Wegovy tablet (oral semaglutide) has led some readers to assume tirzepatide has followed suit. It hasn't, yet. The NHS tirzepatide medicines page reflects only the licensed injection form.

A quick check worth doing: if you're considering any tirzepatide product from an online seller, look up the pharmacy on the GPhC pharmacy register before you proceed. It takes under a minute and confirms whether the seller is authorised to dispense prescription medicines in the UK.

What the licensed Mounjaro KwikPen actually looks like and how it works

The Mounjaro KwikPen is a pre-filled, disposable device. Each pen holds four weekly doses, so one pen covers a full four-week period. You inject it into the abdomen, thigh or upper arm, rotating the site each week. The pen is designed to be straightforward: there's no vial, no mixing and no syringe to handle separately.

Tirzepatide itself is a dual GIP and GLP-1 receptor agonist. Those two gut hormones work together to reduce appetite, slow how quickly the stomach empties and influence blood-sugar regulation. Activating both pathways is what sets Mounjaro apart from GLP-1-only injections. Full detail on how Mounjaro works covers the mechanism in plain language if you'd like to go deeper.

Treatment starts at the 2.5mg weekly dose. That starting strength is about tolerability rather than effect, it gives the body time to adjust before the prescriber steps the dose up. The available strengths are 2.5, 5, 7.5, 10, 12.5 and 15mg. Which strength you reach, and how quickly, depends entirely on your prescriber's assessment and how your body responds. Storage is in the fridge at 2–8°C; the Patient Information Leaflet spells out the exact room-temperature window for when you're travelling.

Where oral tirzepatide fits in, and what to read instead right now

Phase 3 clinical data for an oral tirzepatide formulation exists and Eli Lilly has shared results publicly. The results are promising. But promising trial data and a UK marketing authorisation are different things, and as of summer 2026 the MHRA has not approved an oral tirzepatide product. Pages discussing tirzepatide in pill form can explain where the research stands, but that content is necessarily forward-looking rather than a guide to something you can currently obtain.

Patients who specifically want an oral GLP-1 medicine for weight management do now have a licensed option: the Wegovy tablet (oral semaglutide), approved by the MHRA on 11 June 2026. That is a different active ingredient. If an injectable form doesn't suit you, that distinction is worth knowing, and worth discussing with a prescriber who can look at your full picture. Our weight-loss treatment overview sets out what is currently licensed and available.

For people weighing up costs alongside the choice of form, the Mounjaro cost page gives context on private pricing, including what a legitimate price should include beyond the pen itself.

Getting the right form through the right route

Because tirzepatide is a prescription-only medicine, no UK pharmacy can supply it (in any form) without a valid prescription from a registered prescriber. That's not a bureaucratic hurdle; it's the mechanism that keeps dosing safe and supply genuine. NICE's appraisal of tirzepatide (TA1026) confirms the clinical case for the licensed injection for adults meeting specific BMI and comorbidity criteria, and your prescriber applies that evidence to your individual situation.

Private routes like nume mean no referral and no waiting list, a GPhC-registered prescriber reviews your consultation the same day, not software. The process covers ID verification, live weight confirmation and a clinical review of your health history before anything is prescribed. For more on specific health conditions and tirzepatide suitability, or to look at the broader picture of our clinical team's approach, our clinical team page is a good starting point.

If questions remain (about dosing, storage, or whether the injection form is right for you) our FAQs cover many of the practicalities, and the support team is available seven days a week. When you're ready to take the next step, speaking to our prescribers starts with a free consultation.